CYTOCOM
Cytocom, Inc. a specialty biotech company, founded by patients, specializing in repurposing of drugs that deploys their patented therapies focused on the activation and rebalancing of the body’s immune system. Stimulating the body’s immune system remains one of the most promising approaches in the treatment of Cancers, HIV, Autoimmune Diseases, inflammatory conditions and other chronic infectious diseases.
CYTOCOM
Industry:
Biopharma Biotechnology Health Care
Founded:
2014-01-01
Address:
Fort Collins, Colorado, United States
Country:
United States
Website Url:
http://www.cytocom.com
Total Employee:
11+
Status:
Active
Contact:
1-888-629-4155
Total Funding:
94.28 M USD
Technology used in webpage:
Euro Unified Layer BlueHost
Similar Organizations
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-10-19 | Cleveland BioLabs | Cleveland BioLabs acquired by Cytocom | N/A |
| 2020-07-20 | ImQuest Life Sciences | ImQuest Life Sciences acquired by Cytocom | N/A |
Investors List
Avenue Capital Group
Avenue Capital Group investment in Post-IPO Debt - Cytocom
Adit Ventures
Adit Ventures investment in Post-IPO Debt - Cytocom
The Global Emerging Markets Group
The Global Emerging Markets Group investment in Post-IPO Equity - Cytocom
Official Site Inspections
http://www.cytocom.com
- Host name: server276-4.web-hosting.com
- IP address: 68.65.123.126
- Location: Los Angeles United States
- Latitude: 34.0318
- Longitude: -118.4252
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90064
More informations about "Cytocom"
Cytocom - Crunchbase Company Profile & Funding
Organization. Cytocom . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Cytocom is a biopharmaceutical company …See details»
Cytocom - Org Chart, Teams, Culture & Jobs - The Org
Cytocom, Inc. is a clinical-stage biopharmaceutical company developing novel second-generation immune therapies to deliver immune homeostasis based on proprietary platforms. The …See details»
Cytocom, Inc. Announces Plan to Adopt New Corporate Name …
Aug 31, 2021 Cytocom, Inc. emerged as a publicly-traded entity following the merger between the former Cleveland BioLabs and the formerly private Cytocom Inc., completed on July 27, …See details»
Cytocom - businessabc.net
Nov 21, 2024 Founded in 2012, Cytocom is a privately-held, healthcare technology company located in Boston. From its initial development of a clinical research platform to its focus today …See details»
Cytocom's Leadership Team Team - Team members and org chart
Other teams at Cytocom. View all +6. CEO and Executive Team. 9 members +1. Board of Directors. 4 members. The Org helps you hire great candidates. It takes less than ten minutes …See details»
Cytocom Company Profile: Overview and Full News Analysis
Cytocom, Inc. is a Colorado-based company specializing in novel immunotherapies targeting autoimmune diseases, infectious diseases, inflammatory diseases, and cancers. The company …See details»
Cytocom, Inc. Announces Plan to Adopt New Corporate Name …
Aug 31, 2021 Cytocom, Inc. Nichol Ochsner Senior V.P. Investor Relations and Corporate Communications (732) 754-2545 [email protected] Tiberend Strategic Advisors, Inc. Maureen …See details»
Cytocom | VentureRadar
Statera Biopharma USA Publicly Traded Statera Biopharma, Inc. (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting …See details»
Cytocom Inc. Provides Update on Completed Merger with …
FORT COLLINS, Colo., Aug. 5, 2021 -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune …See details»
Cytocom and Cleveland BioLabs Announce Definitive Merger …
Oct 19, 2020 Merger to create a single public company focused on the development and commercialization of immunotherapies for oncology, infectious disease, inflammation and auto …See details»
Cytocom Inc. Provides Update on Completed Merger with
Aug 5, 2021 Contacts: Cytocom Inc. Nichol Ochsner Senior V.P. Investor Relations and Corporate Communications(732) [email protected] Tiberend Strategic …See details»
Cytocom, Inc. Issues Shareholder Letter - PR Newswire
Oct 21, 2020 /PRNewswire/ -- Cytocom, Inc., a leading biopharmaceutical company in the area of immune-modulation, ... a drug development company and contract research organization.See details»
Cytocom Inc. Announces Completed Merger with Cleveland BioLabs
Jul 28, 2021 Cytocom is developing therapies designed to elicit directly within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating …See details»
Cytocom Inc. Announces Completed Merger with Cleveland BioLabs
Jul 28, 2021 As previously reported, the newly combined company will operate as "Cytocom, Inc." under the leadership of the existing Cytocom management team led by CEO Michael K. …See details»
Cytocom, Inc. and La Jolla Institute for Immunology Announce Five …
Aug 13, 2021 Cytocom to fund research in cancer, autoimmune and inflammatory conditions, and infectious diseases and applications to clinical-stage therapies Research to accelerate …See details»
cleveland biolabs inc and cytocom inc announce call to discuss ...
Nov 13, 2024 Cleveland BioLabs Inc. and Cytocom Inc. are making waves in the biotech industry with a significant announcement that could reshape their futures. Both companies …See details»
Cytocom Inc. Provides Updates on Key Clinical Programs for …
Aug 9, 2021 Cytocom is partnering with ICON plc, a global contract research organization (CRO), to manage the trial, and expects to begin enrolling patients by year-end 2021. …See details»
Cytocom, Inc. Receives Commitments for $90 Million in Equity and …
Jul 29, 2021 Cytocom, Inc. Nichol Ochsner Senior V.P. Investor Relations and Corporate Communications (732) 754-2545 [email protected] Tiberend Strategic Advisors, Inc.See details»
Cytocom Inc. Announces Completed Merger with Cleveland BioLabs
Jul 28, 2021 New company to operate as "Cytocom, Inc." with its common stock traded on Nasdaq FORT COLLINS, Colo., July 28, 2021 -- Cytocom Inc. ("Cytocom" or "Company"), a …See details»